checkmate pharmaceuticals logo

Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a cancer R&D driven startup developing cancer immunotherapy by utilizing immune checkpoint proteins inhibitors combined with an immune activator to stimulate the CTL attack against the tumor.

Checkmates founder and CEO, Dr. Art Krieg, discovered CpG DNA in 1994. CpG DNA (Toll-like receptor 9 agonist) has been found as the strongest at activating anti-tumor CTLs response.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://checkmatepharma.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1 Broadway, 14th Floor,MA 02142
Cambridge
United States
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

Checkmate is validating an approach that will combine the ability of CpG DNA to activate an anti-tumor T cell response along with checkpoint inhibition to overcome a tumors ability to mute the immune response.

In Aug 2015, Checkmate acquired licence of clinically validated virus-like particle (VLP) platform and clinical product (CYT003) along with technologies related to oligonucleotide synthesis & VLP delivery from Cytos Biotechnology, for its use in oncology.

In Aug 2015, Checkmate Pharmaceuticals received $20 Mn series A financing from Sofinnova Ventures and venBio.